今夜，又见证历史！

Core Viewpoint - The U.S. stock market is experiencing volatility, with Eli Lilly becoming the first healthcare company to reach a market capitalization of $1 trillion, driven by investor enthusiasm for its weight loss drugs [1][4]. Market Performance - On November 21, U.S. stock indices showed mixed results, with the Dow Jones rising over 220 points, while the Nasdaq index experienced fluctuations and the S&P 500 saw a slight increase [2]. - The market's recovery was aided by dovish signals from a Federal Reserve official, increasing the likelihood of a rate cut in December to over 70% [2]. - Despite a significant rally earlier in the week, the S&P 500 is down over 2% for the week, with the Dow and Nasdaq also experiencing declines of nearly 3% [3]. Eli Lilly's Milestone - Eli Lilly's market capitalization surpassed $1 trillion, making it the largest pharmaceutical company globally and the second U.S. company outside the tech sector to achieve this milestone [4]. - The surge in Eli Lilly's stock price, which rose 1.7% at one point, is largely attributed to the growing interest in its GLP-1 class of drugs for obesity and diabetes treatment [4]. - The market for Eli Lilly's next-generation oral weight loss drug is projected to reach $95 billion by 2030 [4]. Competitive Landscape - Eli Lilly has captured nearly 58% of the market share in the GLP-1 drug segment, which includes Ozempic and Wegovy [5]. - Analysts note that Eli Lilly has rapidly gained market share, outperforming its competitor Novo Nordisk, which initially led in the obesity treatment space [5]. - The company's stock has increased by 37% this year and is expected to rise by 32% in 2024, positioning it as a potential leader in the global weight loss drug market [5].